Haller J. Smith

PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.

PURPOSE To determine the cost-effectiveness of olaparib, a PARP inhibitor, as maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer. METHODS Two separate decision analysis models compared the cost of observation versus olaparib maintenance therapy in patients with PS recurrent ovarian cancer, one for patients with a germline BRCA1/2 mutation and one for patients with wild-type BRCA1/2. Patients received six cycles of paclitaxel and carboplatin. Drug costs were estimated using 2014-2015 wholesale acquisition costs. The cost of olaparib was estimated at

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth

13,440 per month. Rate of germline BRCA1/2 mutation was estimated at 20%. Progression-free survival was determined from published data. Incremental cost-effectiveness ratios (ICERs) per progression-free life-year saved (PF-LYS) were calculated. A sensitivity analysis estimated the cost at which olaparib would be cost-effective. RESULTS We estimated that there were 5549 patients diagnosed with PS recurrent ovarian cancer in the United States annually. The cost of observation in 1110 patients with a BRCA1/2 mutation was

The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis

5.5 million (M) versus

Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review

169.2M for maintenance therapy with olaparib. The ICER for olaparib maintenance therapy in patients with a BRCA mutation was

Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy

258,864 per PF-LYS. If the cost of olaparib was decreased to

Perioperative morbidity and mortality in octogenarians with ovarian cancer.

2500 per month, the ICER was

Enhanced Recovery After Surgery in Surgical Specialties: Gynecologic Oncology

49,584. For the 4439 patients with wild-type BRCA, the cost of maintenance therapy was

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

444.2M; the ICER was

Impact of enhanced recovery after surgery (ERAS) protocol on the gastrointestinal tract in gynecologic oncology patients undergoing laparotomy

600,552 per PF-LYS. CONCLUSIONS For patients with a germline BRCA1/2 mutation, maintenance therapy with olaparib is not cost-effective with an ICER of

Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman

258,864 per PF-LYS. To achieve an ICER of less than